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ABSTRACT
Angiogenesis defines the process in which new vessels grow from
existing vessels. Using the mouse retina as a model system, we
show that cysteine-rich motor neuron 1 (Crim1), a type I
transmembrane protein, is highly expressed in angiogenic endothelial
cells. Conditional deletion of the Crim1 gene in vascular endothelial
cells (VECs) causes delayed vessel expansion and reduced vessel
density. Based on known Vegfa binding by Crim1 and Crim1
expression in retinal vasculature, where angiogenesis is known to be
Vegfa dependent, we tested the hypothesis that Crim1 is involved in
the regulation of Vegfa signaling. Consistent with this hypothesis, we
showed that VEC-specific conditional compound heterozygotes for
Crim1 and Vegfa exhibit a phenotype that is more severe than each
single heterozygote and indistinguishable from that of the conditional
homozygotes. We further showed that human CRIM1 knockdown in
cultured VECs results in diminished phosphorylation of VEGFR2, but
only when VECs are required to rely on an autocrine source of
VEGFA. The effect of CRIM1 knockdown on reducing VEGFR2
phosphorylation was enhanced when VEGFA was also knocked
down. Finally, an anti-VEGFA antibody did not  enhance the effect of
CRIM1 knockdown in reducing VEGFR2 phosphorylation caused by
autocrine signaling, but VEGFR2 phosphorylation was completely
suppressed by SU5416, a small-molecule VEGFR2 kinase inhibitor.
These data are consistent with a model in which Crim1 enhances the
autocrine signaling activity of Vegfa in VECs at least in part via
Vegfr2.
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INTRODUCTION
Angiogenesis defines the process in which new vessels grow from
existing vessels through branching morphogenesis (Phng and
Gerhardt, 2009; Geudens and Gerhardt, 2011). During
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angiogenesis, some vascular endothelial cells (VECs) in the
originally quiescent vessels are induced to become tip cells. 
These cells are polarized and extend filopodia to probe
microenvironmental cues, and migrate to lead the elongation of
new vessel branches (Gerhardt et al., 2003). The VECs adjacent to
tip cells become stalk cells, which proliferate and contribute to
lumen formation (Gerhardt et al., 2003). Fusion of new sprouts in
a process called anastomosis contributes to vascular network
formation (Geudens and Gerhardt, 2011). This draft network then
undergoes extensive remodeling to become functional (Potente et
al., 2011). Dysregulated angiogenesis occurs in many pathological
processes, including cancer (Gasparini et al., 2005), diabetic
retinopathy (Crawford et al., 2009), retinopathy of prematurity
(Flynn and Chan-Ling, 2006), and age-related macular
degeneration (Jager et al., 2008), in which anti-angiogenic therapy
can be of value (Gasparini et al., 2005).
The vascular endothelial growth factor (Vegf) family members are
key regulators of vessel development and homeostasis. Vegfa is an
indispensable pro-angiogenic factor in almost all non-pathological
and pathological angiogenesis (Carmeliet and Jain, 2011). Vegfa
signals via vascular endothelial growth factor receptor 2 (Vegfr2;
Kdr – Mouse Genome Informatics), a conventional tyrosine kinase
receptor. Vegfr1 (Flt1 – Mouse Genome Informatics) is an inhibitory
receptor because it binds Vegfa avidly but does not signal with high
activity (Shibuya, 2001). There is also a soluble isoform of Vegfr1
that inhibits Vegfa through sequestration (Shibuya, 2001). During
angiogenesis, Vegfa signals to VECs to promote tip cell formation
[by enhancing expression of Dll4 (Phng and Gerhardt, 2009;
Geudens and Gerhardt, 2011)], tip cell migration (Gerhardt et al.,
2003), stalk cell proliferation (Gerhardt et al., 2003) and VEC
survival via Akt (Gerber et al., 1998). Vegfr3 (Flt4 – Mouse
Genome Informatics), a receptor for Vegfc, is restricted to the
lymphatic vessels in the adult, but is upregulated during
developmental angiogenesis in tip cells and during pathological
angiogenesis (Tammela et al., 2011). It has recently been shown that
VECs themselves are a source of Vegfa and that the ‘private loop’
of signaling via Vegfr2 within the VECs is crucial (Lee et al., 2007;
Segarra et al., 2012). Mice in which Vegfa was deleted specifically
in VECs showed postnatal mortality associated with vascular
degeneration (Lee et al., 2007), suggesting a role for autocrine Vegfa
in vascular homeostasis. Although it has been shown that
endothelial cells upregulate Vegfa production under stress
conditions, such as hypoxia (Namiki et al., 1995; Lee et al., 2007),
other molecules involved in regulation of the ligand and downstream
effectors of this pathway are largely unknown.
Cysteine-rich motor neuron 1 (Crim1) is a type I transmembrane
protein that has N-terminal homology to insulin-like growth factor
binding protein (IGFBP) domain and six cysteine-rich von Willebrand
factor C (vWC) repeats, which are similar to those of chordin, a BMP
antagonist (Kolle et al., 2000). Crim1 is expressed in multiple tissues
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and cell types, including the vertebrate CNS (Kolle et al., 2003;
Pennisi et al., 2007), kidney (Wilkinson et al., 2007), eyes [including
lens (Lovicu et al., 2000)] and the vascular system (Glienke et al.,
2002; Pennisi et al., 2007; Wilkinson et al., 2007). It has been
suggested that Crim1 has a role in vascular tube formation in vitro
(Glienke et al., 2002). It is localized in endoplasmic reticulum and
accumulates at cell-cell contacts upon stimulation of endothelial cells
(Glienke et al., 2002). Mice homozygous for a gene-trap mutant allele
(Crim1KST264) or germline mutants (Chiu et al., 2012) display perinatal
lethality with defects in multiple organs, including hemorrhagic
necrosis and enlarged glomerular capillary lumens (Wilkinson et al.,
2007). The molecular function of Crim1 has been somewhat
enigmatic, but it is known to form complexes with N-cadherin and β-
catenin (Ponferrada et al., 2012) and to bind growth factors including
Vegfa (Wilkinson et al., 2007; Wilkinson et al., 2009). In the
glomerulus of the kidney, Crim1 on the cell surface of podocytes is
proposed to regulate the delivery of Vegfa from podocytes to
endothelial cells (Wilkinson et al., 2007; Wilkinson et al., 2009).
In the current study, based on the known Vegfa binding by Crim1
(Wilkinson et al., 2007) and the expression of Crim1 in retinal
vasculature, we tested the hypothesis that Crim1 is involved in the
autocrine activity of Vegfa. Consistent with this, VEC-specific
conditional compound heterozygotes for Crim1 and Vegfa showed a
phenotype more severe than each single heterozygote and
indistinguishable from that of the conditional homozygotes. Human
CRIM1 knockdown in cultured VECs resulted in diminished
phosphorylation of VEGFR2, but only when VECs are required to
rely on an autocrine source of VEGFA. VEGFA knockdown
enhanced the effect of CRIM1 knockdown on reducing VEGFR2
phosphorylation. An anti-VEGFA antibody did not enhance the
effect of CRIM1 knockdown in reducing VEGFR2 phosphorylation
caused by autocrine signaling, but VEGFR2 phosphorylation was
completely suppressed by SU5416, a small-molecule VEGFR2
kinase inhibitor. These data are consistent with a model in which
Crim1 enhances the autocrine signaling activity of Vegfa in VECs
at least in part via Vegfr2.
RESULTS
Crim1 is expressed in endothelial cells and pericytes
Crim1 is expressed in VECs in vitro and in vivo (Glienke et al., 2002).
To examine the expression pattern of Crim1 in angiogenic
vasculature, we analyzed flat-mounted preparations of mouse
embryonic hindbrain and postnatal retinas from a Crim1:GFP mouse
line (MGI: 4846966). In the vasculature of both organs, GFP was
expressed in VECs marked by Isolectin IB4 (Fig. 1A-I). Notably, in
the center of the retinal vascular plexus, the GFP intensity was lower
in VECs but also present in smooth muscle cells marked by NG2
(Cspg4 – Mouse Genome Informatics) labeling (Fig. 1E,F,
Fig. 1. Crim1 is expressed in endothelial cells and
pericytes in angiogenic vasculature. (A-F) Flat-mounted
P6 Crim1:GFP mouse retina labeled with isolectin IB4 and
NG2 antibody. Enlarged images of the boxed regions (C-F)
show colocalization of the GFP expression in isolectin-
labeled endothelial cells and NG2-labeled pericytes/smooth
muscle cells (arrowheads). (G-I) GFP signal was also
detected in hindbrain vasculature of the E12.0 reporter
mouse. (J) Representative FACS chart showing the
endothelial cell population sorted from retina. (K) End-point
RT-PCR in sorted endothelial cells and whole retina. For
each primer set, PCR products were amplified with similar
amounts of cDNA and the same cycle number. +/– RT, with
and without reverse transcription. M, DNA size marker. 
(L-Q) Transverse sections of P6 and P10 retina labeled
with Crim1 antiserum. No primary antibody was added in
L,O. (O-Q) Higher magnification images. Arrows indicate
Crim1 expression in endothelial cells; arrowhead indicates
Crim1 expression in another cell type.
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arrowheads). We also isolated CD31+ CD45– VECs from wild-type
P7 mouse retinas by FACS (Fig. 1J). We confirmed cell identity by
end-point RT-PCR detecting the endothelial cell marker Cd31
(Pecam1 – Mouse Genome Informatics) and the pericyte marker
Pdgfrb (Fig. 1K). Crim1 transcripts were detected in retinal VECs
using two different sets of primers (Fig. 1K). Crim1 protein was also
labeled by immunofluorescence in P6 and P10 wild-type retinal
sections using a newly developed antiserum. High immunoreactivity
was observed in VECs labeled by Isolectin IB4 (Fig. 1M,N,P,Q), as
well as in cells associated with the vasculature, which were probably
pericytes (Fig. 1P, arrowheads). The expression of Crim1 in VECs
indicated that it might have a role in vascular development.
Validation of the Crim1flox allele
Crim1flox mice were crossed with the germline-expressed EIIa-Cre
line to generate the Crim1Δflox allele. Mice homozygous for this
allele did not show lethality until embryonic day (E) 17.5
(supplementary material Fig. S2A), but postnatally we identified
only three live pups from over 20 litters, indicating that
homozygotes died perinatally. Crim1Δflox/Δflox embryos exhibited
anomalies that included peridermal blebbing, edema, hemorrhage
(especially in the CNS), eye hypoplasia and syndactyly
(supplementary material Fig. S2B-T). These changes phenocopy
defects described in mice homozygous for the hypomorphic allele
Crim1KST264 (Pennisi et al., 2007) and another germline null allele
(Chiu et al., 2012) but occur with higher penetrance and severity
(supplementary material Fig. S2B). These data validate Crim1flox as
a conditional loss-of-function allele.
Deletion of Crim1 in VECs results in defective vascular
development in the retina
We combined the Pdgfb-iCreER allele with Crim1flox and used daily
intraperitoneal injection of tamoxifen starting at P1 or P7
(supplementary material Fig. S1C) to elicit Cre recombinase activity.
Pdgfb-iCreER mice, upon tamoxifen administration, exhibit specific
Cre activity in VECs including tip cells (Claxton et al., 2008)
(supplementary material Fig. S1D). The Crim1flox allele was
effectively recombined in retinal VECs as shown by genotyping
PCR of DNA from FACS-sorted P7 endothelial cells (supplementary
material Fig. S1E); the recombined Crim1flox allele was detected in
tail DNA and retina DNA only when mice had the Pdgfb-iCreER
allele (supplementary material Fig. S1B,E).
In the first postnatal week, a primary vascular plexus grows
within the ganglion cell layer of the mouse retina through sprouting
and anastomosis, expanding from the optic stalk and reaching the
periphery by ~P8 (Fruttiger, 2007). Tamoxifen-injected Crim1flox/flox;
Pdgfb-iCreER pups showed delayed radial expansion of vasculature
from center to periphery over a P5-P7 timecourse as compared with
Cre-negative control littermates (Crim1flox/flox or Crim1flox/+)
(Fig. 2A-C). More distinctively, vessel density as quantified by
branchpoint number was also reduced in both the angiogenic front
and remodeling plexus area behind the front (Fig. 2D-F).
Starting at P7-P8, vessels sprout into the outer plexiform layer
(OPL) and then turn, sprout and connect to form the deep vascular
layer that resides between the OPL and the photoreceptors (Fruttiger,
2007). Crim1flox/flox; Pdgfb-iCreER pups injected with tamoxifen
from P7 to P10 exhibited a delayed invasion of vasculature into the
deepest layer (supplementary material Fig. S3A-D), as shown by
fewer vertical sprouts, reduced branchpoint number and reduced
total vessel length (supplementary material Fig. S3E-G). Combined,
these data showed that endothelial Crim1 plays a role throughout
retinal vascular development.
Loss of Crim1 from endothelial cells caused abnormal
vessel morphology and compromised VEC proliferation
The initial density of the sprouting vasculature can be affected by
tip cell number (Hellström et al., 2007; Phng et al., 2009; Larrivée
et al., 2012). The angiogenic front in Crim1 VEC conditional
mutants was hypocellular compared with that of wild-type
littermates, as indicated by Erg1/2/3 antibody labeling of the VEC
nuclei (Fig. 2G-I). In addition, a much higher occurrence of vessel
segments of small caliber was observed in Crim1 VEC conditional
mutant mice (Fig. 2E,H).
Two-hour BrdU incorporation showed a reduced number of S-
phase VECs in the conditional mutant pups (Fig. 2J-L). Tip cells of
the Crim1 VEC conditional mutant mice exhibited a mildly reduced
density of filopodia, but these filopodia were still closely attached
to the underlying astrocytes (Fig. 2M-Q). Expression of the Notch
pathway target Vegfr3 was normal in VEC conditional mutants
(supplementary material Fig. S4), suggesting that loss of Crim1 from
VECs was unlikely to disrupt the Notch signaling pathway.
Endothelial loss of Crim1 results in defective cell adhesion
molecule distribution and precocious vessel regression
Previous studies from our laboratory indicated that Crim1 has an
active role in promoting neuroepithelium cell adhesion through
regulation of cadherin-catenin complexes (Ponferrada et al., 2012).
Other investigators also showed that Crim1 accumulates at
endothelial cell-cell contacts under certain conditions (Glienke et al.,
2002). Given the important role that the adhesion molecule VE-
cadherin plays in initiating anastomosis (Hoelzle and Svitkina,
2012) and maintaining vessel stability (Dejana et al., 2009; Phng et
al., 2009), we assessed the possibility of a cell adhesion anomaly in
Crim1flox/flox; Pdgfb-iCreER mouse retinal vasculature.
We observed an increase in vessel segments with discontinuous
VE-cadherin labeling in Crim1 conditional mutants (Fig. 3A-L) (one
vessel segment is defined as an isolectin-labeled connection between
two branchpoints). This change was more significant at the
angiogenic front (Fig. 3M). VE-cadherin-negative segments were
usually of reduced caliber. In addition, podocalyxin labeling, which
marks the apical/luminal side of the vessels, was missing in VE-
cadherin-negative regions (Fig. 3N-P,R-T, arrowheads). In summary,
Crim1 VEC conditional mutant mice had a higher percentage of
thin, cadherin-deficient, non-lumenized vessel segments.
Normally, vessel pruning occurs mostly around arteries where the
oxygen level is high (Adini et al., 2003; Phng et al., 2009).
Regressed vessel segments appear as ‘vessel ghosts’, which are
labeled for vascular basement membrane markers such as collagen
IV but lack isolectin-positive VECs (Phng et al., 2009). In
Crim1flox/flox; Pdgfb-iCreER pups, there was a significant increase in
vessel ghosts at the angiogenic front (Fig. 4A-D,M) but no
significant increase within the remodeling plexus (Fig. 4E-H,M). We
observed several cases of retracted sprouts (Fig. 4I,J) and vessel
fragments completely disconnected from the vessel bed (Fig. 4K,L).
We also labeled active caspase 3, an early marker for apoptosis
(Fig. 4N-Q). The VEC apoptosis index was significantly higher in
Crim1flox/flox; Pdgfb-iCreER retinas than in control retinas
(Fig. 4N,O,R). We measured the distance of dying vessel
fragments from the center of the retina and found that the increase
in apoptosis in the VEC conditional mutant mice was most
apparent within the region between 60% and 70% of the distance
to the edge of the angiogenic front. This corresponds to the more
angiogenically active vessel front (Fig. 4S). Mural cells recruited
to newly formed capillaries are also crucial for vessel stability
(Gerhardt and Betsholtz, 2003). In Crim1flox/flox; Pdgfb-iCreER D
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mutant pups, the attachment of desmin+ (supplementary material
Fig. S5) or NG2+ pericytes (data not shown) to VECs at the
angiogenic front was not compromised, although smooth muscle
actin (SMA) showed mildly reduced labeling around arteries
(supplementary material Fig. S5E-H). This suggested that
depletion of Crim1 from VECs did not have a significant effect on
mural cells. Combined, these data suggest that loss of Crim1 from
VECs causes instability of newly formed vessels, resulting in
vessel fragmentation and precocious regression.
Crim1 and Vegfa function cooperatively in retinal
vasculature development
Previous studies showed that Crim1, via its cysteine-rich motif, is
able to physically bind ligands bearing a cysteine-knot motif,
Fig. 2. Loss of Crim1 from endothelial cells causes reduced vessel growth in the primary plexus of the retinal vasculature. (A,B,D,E) Flat-mounted P6
mouse retina labeled with isolectin IB4. Crim1 VEC conditional mutant mice showed reduced vessel expansion to the periphery, as quantified in C. (F) Vessel
density measured by counting branchpoint number in randomly selected 200 μm × 200 μm fields (five fields per retina). (G,H) High-magnification images
showing anomalies in vascular morphology at the angiogenic front in P6 Crim1 VEC mutant mice. (I) Quantification of Erg1/2/3 antibody-labeled VEC nuclei
per field. (J-L) Two-hour BrdU incorporation experiment showed a reduced VEC proliferation profile in P5 Crim1 VEC mutant pups. BrdU incorporation (cell
number) was normalized to vessel-covered area, as labeled by Isolectin IB4. (M-P) Filopodia in Crim1 VEC conditional mutant mice extend along a preformed
astrocyte template labeled with Pdgfrα antibody. Filopodia number was quantified and normalized to the outline of the angiogenic front. (C,F,I,L,Q) M,
Crim1flox/flox; Pdgfb-iCreER pups; C, control littermates. At least five retinas of each genotype were analyzed in every experiment. Error bars represent s.e.m.
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including several BMPs, PDGF and VEGFA, before their secretion
(Wilkinson et al., 2003; Wilkinson et al., 2007). This, and the
Vegfa dependence of retinal angiogenesis, raised the possibility
that Crim1 might regulate Vegfa activity. In the retina, in the first
postnatal week, Vegfa transcript is found in astrocytes and neurons
(Fruttiger, 2007; Rao et al., 2013). Vegfa protein becomes tethered
to the extracellular matrix of astrocytes in avascularized regions
ahead of the angiogenic front (Gerhardt et al., 2003; Stenzel et al.,
2011). In addition to paracrine Vegfa, VEC-derived autocrine
Vegfa signaling has been implicated in vessel homeostasis (Lee et
al., 2007).
To examine whether autocrine signaling is also required for
angiogenesis in vivo, we generated Vegfa VEC conditional knockout
mice by crossing the Pdgfb-iCreER line to the VegfaloxP line (Gerber
et al., 1999) and induced Cre activity by tamoxifen injection.
Compared with Cre-negative control littermates, conditional
heterozygotes and homozygotes showed a reduced vascularized area
(Fig. 5A-C) and a Vegfa dose-dependent reduction in vessel density
(Fig. 5A,B,D). This phenotype has many similarities to the Crim1
VEC conditional phenotype. In particular, Vegfa conditional deletion
results in many more collagen IV+, isolectin-negative vessel ghosts
(supplementary material Fig. S6A,B,E,F) and vessel segments that
show discontinuous VE-cadherin labeling (supplementary material
Fig. S6C,D,G,H). Furthermore, like the Crim1 conditional mutant,
in the Vegfa conditional mutant discontinuous VE-cadherin labeling
correlated with the absence of podocalyxin, suggesting the absence
Fig. 3. Abnormal adhesion junction distribution in Crim1
VEC conditional mutants. (A-L) Antibody labeling in flat-
mounted retina preparations shows VE-cadherin distribution
in the P6 angiogenic front (A-H) and P7 remodeling plexus 
(I-L) areas. White and pink arrowheads point to vessel
segments without continuous VE-cadherin distribution.
(M) Quantitation of vessel segments without continuous
junctional VE-cadherin signal (normalized to total Isolectin
IB4-labeled segments). M, Crim1flox/flox; Pdgfb-iCreER pups;
C, control littermates. At least five retinas of each genotype
were analyzed at P6 or P7.  Error bars represent s.e.m. 
(N-U) VE-cadherin and podocalyxin colabeling showing that
VE-cadherin-deficient vessel segments, which occurred more
frequently in Crim1flox/flox; Pdgfb-iCreER pups, did not have a
lumen (white and yellow arrowheads).
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of a lumen. Combined, these data confirm that VECs are a
biologically important source of Vegfa (Lee et al., 2007) and
indicate that the Crim1 and Vegfa VEC loss-of-function phenotypes
are very similar.
One means to assess whether Crim1 might regulate Vegfa
function in vivo is to generate compound conditional mutants and
perform a quantitative assessment of the phenotype. In this way, it
is possible to determine whether two molecules contribute to the
same biological process. Thus, we combined the VegfaloxP, Crim1flox
and Pdgfb-iCreER alleles and found that both VegfaloxP/+; Pdgfb-
iCreER and Crim1flox/+; Pdgfb-iCreER heterozygotes showed mildly
reduced expansion of the vasculature as well as vessel density
(Fig. 5H,I compared with 5E,F). Interestingly, the VegfaloxP/+;
Crim1flox/+; Pdgfb-iCreER double heterozygotes exhibited much
more severely defective angiogenesis than either of the single
heterozygotes (Fig. 5H-J) and recapitulated the retinal vascular
phenotypes of Crim1 or Vegfa VEC-specific knockouts (Fig. 5K,L).
This synthetic phenotype suggests that Crim1 and Vegfa function in
the same pathway.
CRIM1 promotes autocrine VEGFA-VEGFR2 signaling within
endothelial cells
In order to examine directly the possibility that Crim1 regulates
Vegfa signaling, we established lentiviral shRNA-mediated
Fig. 4. Depletion of Crim1 from endothelial cells causes precocious vessel regression. (A-H) Flat-mounted retinas labeled with Isolectin IB4 and collagen
IV antibody. Collagen IV-positive and Isolectin IB4 labeling-negative vessel segments represented regressed capillaries, e.g. vessel ghosts (filled arrowheads)
and retracted sprouts (empty arrowheads). The increase in vessel ghosts was more obvious at the angiogenic front (A-D) than in the remodeling plexus (E-H).
Several cases of long retracted sprouts (I,J) or endothelial cells detaching from the vessel bed (K,L) were observed. (M) Quantification of vessel ghosts. 
(N-Q) Active caspase 3 labeling of retinas. Vessel segments with active caspase 3-labeled endothelial cells increase in Crim1 conditional mutant pups (O,
arrows). Active caspase 3 labeling coincided with DNA fragmentation (P,Q, arrows). (R) Quantification of vessel segments with active caspase 3-labeled
endothelial cells. (S) Occurrence of active caspase 3-positive vessel segments at different distances from the center of the retina (relative to vessel expansion);
*P<0.05. (M,R,S) M, Crim1flox/flox; Pdgfb-iCreER pups; C, control littermates. At least five retinas of each genotype were analyzed in every experiment. Error
bars represent s.e.m.
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knockdown of CRIM1 in human umbilical vein endothelial cells
(HUVECs). Two different shRNAs were able to knock down
CRIM1 by 60-70% at the protein (Fig. 6A) and transcript (Fig. 7D)
levels. Measured by MTT assay, the growth of CRIM1 knockdown
HUVECs cultured in complete medium was greatly suppressed
(Fig. 6A), suggesting a functional requirement. The localization of
VE-cadherin and β-catenin as well as of VEGFR2 was unchanged
in these knockdown cells (supplementary material Fig. S7A-F,J-O).
To test directly whether CRIM1 is involved in VEGFA-VEGFR2
signaling, we stimulated HUVECs with recombinant VEGFA and
assessed the VEGFR2 phosphorylation level using ELISA (Fig. 6B).
With exogenous VEGFA at 80 ng/ml, CRIM1 knockdown HUVECs
showed no change in the ratio of phosphorylated to total VEGFR2
(Fig. 6B). When we tested different concentrations of exogenous
VEGFA (2 to 20 ng/ml), CRIM1 knockdown also had no effect on
VEGFR2 phosphorylation (supplementary material Fig. S8B).
Interestingly, however, when we cultured HUVECs in VEGFA-
deficient medium for 24 hours and added Na3VO4 to inhibit
phosphatase activity, we recorded a significant reduction of
VEGFR2 phosphorylation in the CRIM1 knockdown cells. This
response was quantified by ELISA (Fig. 6C) but was also observed
by immunoblot (Fig. 6D). These data suggested that CRIM1
modulates the autocrine signaling response to VEGFA.
To examine this possibility further, we assessed the relative
impact and the combined impact of VEGFA and CRIM1
knockdown on the growth of HUVECs and on VEGFR2 signaling.
In complete medium with a low supplemental level of VEGFA (~2
ng/ml), VEGFA or CRIM1 knockdown HUVECs exhibited slower
growth kinetics (Fig. 7A), as shown previously (Fig. 6A). In
addition, CRIM1/VEGFA double-knockdown cells showed a more
Fig. 5. VEC-derived Crim1 and Vegfa function
cooperatively in retinal vasculature
development in vivo. (A,B) Flat-mounted P6
retina preparations labeled with Isolectin IB4
showing slightly reduced vessel expansion to
the periphery of the retina and greatly
decreased vessel density in Vegfa VEC
conditional mutant pups. (C,D) Quantitation of
vascularized area (normalized to retina size)
and vessel density, as measured by branchpoint
number in randomly selected fields. (E-J) Flat-
mounted P6 retina preparations of the indicated
genotypes labeled with Isolectin IB4.
(K,L) Quantitation of vascularized area
(normalized to retina size) and vessel density of
retinal vasculature from mice of the indicated
genotypes. At least five retinas of every
genotype were analyzed. Numbers of
Crim1flox/flox; Pdgfb-iCreER and VegfaloxP/loxP;
Pdgfb-iCreER retinas were obtained from other
crosses (see Fig. 2C,F and Fig. 7C,D) and
reused here. *P<0.05; **P<0.01; ***P<0.005;
****P<0.001; NS, not significant. Error bars
represent s.e.m. Scale bars: 250 μm. 
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severe and statistically distinct effect than either single knockdown
(Fig. 7A,B, green trace). In similar experiments assessing cell
number after 48 hours, we found that the effects of single and
combined knockdowns were not compensated by additional
exogenous recombinant VEGFA (Fig. 7B). When we assessed
growth kinetics for CRIM1 knockdown HUVECs in serum-free,
VEGF-deficient medium, we found that the cell number actually
decreased (supplementary material Fig. S8A), indicating that some
cells die, as might be expected with limited VEGFA and limited
alternative survival stimuli. A comparison of the separate or
combined effects of VEGFA and CRIM1 knockdown showed that
under these conditions, as well, the double knockdown produced
the most severe effect (Fig. 7C). An assessment by quantitative
PCR of the expression levels of BCL2, a known anti-apoptosis
factor, and of BAX, a pro-apoptosis factor, showed that the former
exhibited reduced expression whereas the latter exhibited an
increase with VEGFA, CRIM1 and combined VEGFA/CRIM1
knockdown (Fig. 7D). This establishes that VEGFA and CRIM1
affect the same target genes in a survival pathway that functions
within VECs.
The differential effects of an anti-VEGFA antibody (Avastin) and
a VEGFR2 kinase activity inhibitor have been used to show that
there is an exclusively autocrine signaling pathway in VECs (Lee et
al., 2007). Using VEGFR2 phosphorylation in the presence of
orthovanadate in minimal medium as a readout for autocrine
signaling activity, we assessed the relative consequences of VEGFA
or CRIM1 knockdown and determined whether Avastin or the
VEGFR2 kinase activity inhibitor SU5416 could modulate
signaling. As already shown, VEGFA or CRIM1 knockdown had
very similar consequences for VEGFR2 phosphorylation (Fig. 7E).
In addition, we found that Avastin had a very limited ability to
suppress VEGFR2 phosphorylation, whereas SU5416 abrogated this
completely. Quantitatively, Avastin suppressed VEGFR2
phosphorylation by ~25%. This means that 75% of the signaling
activity can be attributed to an Avastin-resistant, autocrine signaling
pathway. Since CRIM1 knockdown can suppress VEGFR2
phosphorylation by significantly more than this, there is a strong
argument that, like VEGFA knockdown, CRIM1 knockdown also
suppresses autocrine signaling by endogenous VEGFA. This notion
is reinforced by the observation that, when CRIM1 and VEGFA
knockdown are combined under the same conditions, there is a
greater effect than either single knockdown on VEGFR2
phosphorylation (Fig. 7F). Together, these data suggest that CRIM1
regulates the activity of VEGFA within the autocrine pathway
known to be active within VECs.
DISCUSSION
We have investigated the function of Crim1 in microvascular
development in vivo. Using conditional deletion of a Crim1flox allele,
we identified a crucial function for Crim1 in the VECs of the
developing retinal vasculature. We also provide evidence that, in
VECs, Crim1 regulates autocrine signaling by Vegfa.
Fig. 6. Crim1 promotes VEGFA-VEGFR2 autocrine signaling in endothelial cells. (A) Growth curve of HUVECs infected by lentiviral particle expressing
scramble shRNA and shRNAs specific for CRIM1. 5000 cells were plated into each well of fibronectin-coated 96-well plates at time zero. Efficiency of knocking
down CRIM1 protein with shRNAs was shown by immunoblot (inset). *P<0.01, three independent experiments. (B) VEGFR2 phosphorylation in response to
VEGFA stimulation. Control and CRIM1-deficient cells were starved for 24 hours and stimulated with 80 ng/ml recombinant human VEGFA for 5 minutes. Cell
lysates were collected and analyzed using phospho-VEGFR2 and VEGFR2 ELISA kits and the ratio of phospho-VEGFR2 and total VEGFR2 readouts
calculated. Measurements were normalized to that of control HUVECs stimulated with recombinant human VEGF. Error bars represent the s.e.m. of three
independent experiments. (C) VEGFR2 phosphorylation without exogenous VEGFA. Control and CRIM1 knockdown HUVECs were cultured in serum-free and
VEGFA-depleted culture medium with or without 0.1 mg/ml Na3VO4 (to inhibit phosphatase activity) for 24 hours. Cell lysates were collected and analyzed
using phospho-VEGFR2 and VEGFR2 ELISA kits and the ratio of the two calculated. All readouts were normalized to that of control HUVECs. Error bars
represent s.e.m. of three independent experiments. (D) Immunoblot of whole cell lysates of control and CRIM1-deficient HUVECs cultured in VEGFA-depleted
medium with or without addition of 0.1 mg/ml Na3VO4. 
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Crim1 stabilizes nascent vessel connections
Angiogenic sprouting forms a draft vessel network that subsequently
undergoes remodeling to become functional (Potente et al., 2011).
Endothelial cell death (Lobov et al., 2005) and retraction of
endothelial cells (Chen et al., 2012) can both contribute to vessel
regression. In the mouse retina, some segment regression is likely
to be triggered by the lack of oxygen demand close to large vessels
(Sun et al., 2005), but, in addition, there is sporadic segment
regression throughout the forming network. Vessel ghosts, which
indicate a regressing segment, can be found even at the advancing
front of an angiogenic network and reveal that remodeling is not
completely restricted spatially. Disruption of certain molecular
pathways, including the Notch pathway (Phng et al., 2009), will
cause excessive vessel regression. The current analysis suggests that
the transmembrane protein Crim1 has a role in stabilizing newly
formed vessel segments; when conditionally mutated in VECs, the
consequence is many more vessel ghosts and overall compromise of
the forming vascular network.
Does Crim1 regulate cadherin adhesion in the retinal
vasculature?
There is evidence that Crim1 can regulate cell-cell adhesion. Crim1
is expressed in adherent cells, especially in those making new cell-
cell contacts (Glienke et al., 2002). Crim1 can also form complexes
with β-catenin and N-cadherin and, consistent with this, in Xenopus
Crim1 stabilizes adhesion junctions and maintains the integrity of
neuroepithelium during morphogenesis (Ponferrada et al., 2012).
These data suggest that some functions of Crim1 could result from
the formation of complexes with VE-cadherin, a cadherin family
member known to be crucial for vascular development (Dejana et
Fig. 7. Relative impacts and
combined impact of VEGFA and
CRIM1 knockdown on VEGFR2
signaling. (A) Growth curve of
HUVECs expressing scramble shRNA
and shRNAs targeting CRIM1, VEGFA
or a combination of both. Colored
asterisks indicate statistical significance
between control and respective
experimental groups. (B) Fold change
in cell number after 48 hours compared
with time zero of cells incubated in
complete medium (EGM-2) or complete
medium with addition of 10 ng/ml
recombinant human (rh) VEGFA.
(A,B) 5000 cells were plated into each
well of 96-well plates at time zero.
(C) Fold change in cell number after
48 hours incubation in serum-free EGM-
2 without addition of supplemental
VEGFA. 20,000 cells were plated in
each well at time zero. (D) Gene
expression measured by quantitative
RT-PCR. Cells were cultured in fresh
complete medium for 24 hours. Level of
mRNA expression was normalized to
that of β-actin. All error bars represent
s.e.m. of three experiments.
(E) VEGFR2 phosphorylation without
exogenous VEGFA. Cells were
incubated for 24 hours in serum-free
EGM-2 without addition of supplemental
VEGFA and with 0.1 mg/ml Na3VO4. In
one set of experiments, the medium
was pre-incubated with 10 μg/ml
Avastin for 2 hours and then applied to
the cells. In another set of experiments,
medium contained 0.5 μM SU5416.
(F) VEGFR2 phosphorylation without
exogenous VEGFA. HUVECs infected
by lentiviral particles expressing
scramble shRNA and shRNAs targeting
CRIM1, VEGFA or a combination of the
two were incubated in serum-free,
VEGFA-depleted medium containing
0.1 mg/ml Na3VO4 for 24 hours before
cell lysates were analyzed by phospho-
VEGFR2 and VEGFR2 ELISA and the
ratio of the two readouts calculated. All
error bars represent s.e.m. of three
independent experiments. *P<0.05;
**P<0.01; ***P<0.005; ****P<0.001; NS,
not significant.
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al., 2009; Strilić et al., 2009). Several features of the Crim1 VEC-
specific conditional knockouts also suggested a consequence for
adhesion, including: (1) an increase in non-perfusable, VE-cadherin-
negative vessel segments; (2) an increase in the bifurcation of tip
cells that mimics the behavior of the VE-cadherin knockdown tip
cells (Montero-Balaguer et al., 2009); and (3) VECs separated from
extending vessels at the angiogenic front, a feature that is also
observed in VE-cadherin endothelial conditional mutants (Gaengel
et al., 2012), suggesting compromise of stable junctions.
However, there is also evidence countering the suggestion that
Crim1 regulates VE-cadherin function. First, when VE-cadherin is
depleted from endothelial cells, vessels show excessive branching
and overgrowth (Gaengel et al., 2012). This contrasted with Crim1
VEC conditional mutants in which vessel connections with
discontinuous VE-cadherin labeling are thin and usually lacking a
lining of endothelial cell nuclei (Fig. 3E-H). Second, although we
could identify α-catenin and β-catenin in immunoprecipitates of VE-
cadherin from cultured confluent endothelial cells, we were not able
to identify Crim1, even when we used an epitope-tagged Crim1 to
increase detection efficiency (data not shown). These findings
suggest that the endothelial cell-cell contact and vessel lumen
defects in Crim1 conditional mutants might be an indirect
consequence of Crim1 loss of function.
Crim1 regulates autocrine Vegfa signaling
Previous studies on Crim1 in various organisms have suggested
that it might regulate the bioavailability of growth factors and
morphogens. In vitro studies demonstrate that Crim1 regulates the
rate of processing and delivery of Bmp4 and Bmp7 to the cell
surface (Wilkinson et al., 2003), probably in the Golgi
compartment. Another study has provided evidence that Crim1 can
physically bind signaling ligands such as Vegfa, Pgf or Pdgf before
their secretion (Wilkinson et al., 2007). In the kidney, Crim1
sequesters Vegfa at the surface of podocytes, so that loss of Crim1
causes excessive Vegfa-Vegfr2 signaling and overgrowth of the
glomerular vasculature (Wilkinson et al., 2007). There are also
invertebrate homologs of Crim1. The C. elegans homolog of
Crim1 (CRM-1) controls body size through regulation of BMP
signaling (Fung et al., 2007). Drosophila crimpy, which has
sequence homology to Crim1, inhibits Glass bottom boat (a BMP
family ligand) in motoneurons during neuromuscular junction
development (James and Broihier, 2011). However, in ovo
knockdown of CRIM1 in Xenopus and Zebrafish and germline loss
of function of Crim1 in mouse do not produce defects in the early
patterning of the body axis (Kinna et al., 2006; Chiu et al., 2012;
Ponferrada et al., 2012), as would be expected if Crim1 were a key
universal regulator of BMP signaling.
Our current findings are consistent with previous analysis of the
phenotype after germline deletion of a Crim1 conditional allele
(Chiu et al., 2012). When a germline loss-of-function homozygous
mutant was produced by recombining our loxP-flanked Crim1 allele
with EIIA-Cre, we found an assemblage of changes (including
hemorrhage, edema and syndactyly) very similar to the phenotype
of the previously characterized insertional (Pennisi et al., 2007) and
germline conditional (Chiu et al., 2012) mutants. Although Crim1
mutant mice show hemorrhage, and Crim1 has been implicated in
binding Vegfa (Wilkinson et al., 2007), germline Crim1 mutant mice
do not show a major failure in early vascular patterning as would be
anticipated if Crim1 were a crucial regulator of Vegfa signaling
(Carmeliet et al., 1996; Ferrara et al., 1996). Combined, these
findings suggest that Crim1 regulates signaling ligands in a
temporally and spatially restricted manner.
It has been shown that VECs can produce Vegfa and that this
autocrine source of Vegfa is indispensable for blood vessel
homeostasis (Lee et al., 2007). The current model suggests that
autocrine Vegfa is crucial for stimulating VEC survival in response
to stress signals such as hypoxia, irradiation and reactive oxygen
species, factors that would be ongoing challenges for mature vessels.
The current analysis, in which we have deleted Vegfa in VECs
during development, also indicates that autocrine Vegfa is important
at developmental stages.
One consequence of VEC-specific Crim1 loss of function is
deficient angiogenesis in the retina. Prompted by data showing that
Crim1 can regulate Vegfa (Wilkinson et al., 2007) and that Vegfa is
the major stimulus for angiogenesis in the retina (Carmeliet and
Jain, 2011), we investigated the possibility that the Crim1 phenotype
resulted from a Vegfa signaling deficiency. We showed that, in the
developing retinal vasculature, Vegfa or Crim1 conditional deletion
in VECs gave very similar phenotypes characterized by an increased
number of vessel ghosts, discontinuous VE-cadherin labeling and an
increase in the number of segments that showed the absence of a
vessel lumen. In addition, conditional compound heterozygotes had
a phenotype more severe than each single heterozygous conditional
mutant and one that was indistinguishable from the homozygous
conditional phenotype. The severe phenotype of the double
heterozygotes is surprising, and this additive effect is consistent with
the hypothesis that this is a synthetic phenotype resulting from the
function of Crim1 and Vegfa in the same pathway.
Culture experiments showed directly that CRIM1 regulates
autocrine VEGFA signaling. First, we showed, as expected, that
proliferation of HUVECs in culture is enhanced by VEGFA
supplementation. In addition, we showed that HUVEC expansion is
almost absent if we used shRNA targeting CRIM1 even with an
exogenous source of VEGFA. Starvation-stimulation experiments
with exogenous VEGFA in CRIM1 knockdown HUVECs did not,
however, reveal any change in the level of VEGFR2
phosphorylation. This suggested that CRIM1 is required for
proliferation and survival in HUVECs, but not because it regulates
the activity of exogenous VEGFA. By contrast, when HUVECs
were denied exogenous VEGFA and required to rely on autocrine
signaling, the outcome for VEGFR2 activation was different. In the
absence of exogenous VEGFA, control HUVECs in serum-free
medium did not proliferate but survived for 2 days or more. CRIM1
knockdown resulted in a rapid reduction in cell numbers over this
timecourse. Accompanying this elevated level of cell death was a
reduced proportion of VEGFR2 in its active, phosphorylated state.
Evidence that the documented VEGFR2 phosphorylation was a
consequence of autocrine signaling came from a comparison of the
effects of an anti-VEGFA antibody, which had a very limited effect,
and that of a small-molecule VEGFR2 inhibitor, which completely
abrogated phosphorylation. Combined, these data support a model
in which CRIM1 regulates VEGFA autocrine activity in the
previously defined ‘private loop’ (Lee et al., 2007) and is consistent
with the observation that Crim1 can form physical complexes with
Vegfa (Wilkinson et al., 2007).
MATERIALS AND METHODS
Generation of the Crim1 conditional allele
We generated a conditional loss-of-function allele, Crim1flox, using
conventional gene targeting. With the very high GC content surrounding
exon 1 (5′ UTR and start codon), we targeted exons 3 and 4 (supplementary
material Fig. S1A). This design left open the possibility that exons 1 and 2
might produce a functional truncated protein. Incorporation of sequences
from the C-terminus of ornithine decarboxylase (cODC) as a signal for rapid D
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degradation (Matsuzawa et al., 2005) was designed to eliminate any
expressed CRIM1 N-terminal sequence. The allele design incorporated loxP
sites into an artificial exon that is initially in reverse orientation. Through
two steps of recombination mediated by a pair of wild-type and a pair of
variant loxP sequences that are incompatible, the ODC degradation signal
was spliced into the mRNA, simultaneously deleting exons 3 and 4. This
allele design strategy has been used previously (Schnütgen et al., 2003).
Mice
Pdgfb-iCreER (Claxton et al., 2008), EIIa-Cre (JAX 003724), Tg(CAG-
Bgeo/GFP) (Z/EG, JAX 003920) and the VegfaloxP line (Gerber et al., 1999)
have been described previously. To induce endothelial cell gene deletion in
Pdgfb-iCreER mouse pups, peanut oil-dissolved tamoxifen (Sigma) was
injected intraperitoneally daily at 20 μg/g body weight. Tamoxifen-injected
Pdgfb-iCreER-negative littermates were used as controls. Birth was defined
as postnatal day (P) 1.
Whole-mount immunofluorescence of retinas
Antibody and isolectin labeling of retinas was performed as previously
described (Stefater et al., 2011) with the following: Alexa 488-Isolectin IB4
(Life Technologies, I21411; 1:1000), Crim1 (homemade rabbit antiserum),
collagen IV (rabbit; Abcam, ab19808; 1:500), BrdU (mouse; Dako, M0744;
1:100), VE-cadherin (rat; BD Biosciences, 555289; 1:100), VE-cadherin
(goat; Santa Cruz, sc-6458; 1:200), CD31 (rat; BD Biosciences, 550274;
1:100), active caspase 3 (rabbit; R&D Systems, AF835; 1:100), podocalyxin
(goat; R&D Systems, AF1556; 1:200), PDGFRα (goat; R&D Systems,
AF1062; 1:100), desmin (rabbit; Abcam, ab15200; 1:500) and smooth
muscle actin (mouse; Sigma, C6198; 1:200).
Cell culture
Pooled HUVECs (Lonza, CC-2519) were cultured on 0.1% gelatin-coated
culture dishes in EGM-2 BulletKit medium (Lonza, CC-3162). Cells before
passage five were used in all experiments. Lentiviral particles containing
shRNA targeting CRIM1 mRNA were acquired from TRC Mission Library
(Invitrogen). Cells at 90% confluence were incubated with diluted lentiviral
particles together with 8 μg/ml polybrene for 16 hours and then treated with
2 μg/ml puromycin for 2 days to enrich the infected cell population. Twenty-
four hours after puromycin removal, cells were used in subsequent
experiments. We tested four different shRNAs targeting CRIM1 and chose
the two that worked most effectively: TRCN0000063860 [shCRIM1(60)]
and TRCN0000063862 [shCRIM1(62)]. Similarly, VEGFA was knocked
down using TRCN0000003343, the effectiveness of which has been
validated before (Segarra et al., 2012).
Growth curve of HUVECs
HUVECs (5000 cells) expressing scramble shRNA or shRNA targeting
CRIM1 or VEGFA were plated in each well of 96-well plates coated with 10
μg/cm2 human fibronectin (Sigma, F2006) and cultured in EGM-2 medium.
To monitor cell survival in VEGFA-deficient medium, 20,000 cells
(confluent) were plated per well and cultured in EGM-2 without addition of
serum or VEGFA.
VEGFR2 activation in cultured HUVECs
To detect the response to exogenous VEGFA, HUVECs expressing shRNAs
were starved in EBM-2 (Lonza, CC-2156) containing only antibiotics and
heparin for 24 hours and stimulated with recombinant human VEGFA
protein (R&D Systems, 293-VE) with 2 mg/ml Na3VO4 for 5 minutes. To
detect VEGFR2 activation by autocrine VEGFA, HUVECs expressing
shRNAs were cultured in the same medium for 24 hours with or without
0.1 mg/ml Na3VO4. For control experiments, cells were cultured in medium
either pre-incubated with 10 μg/ml Avastin (Genentech) or with 0.6 μM
SU5416 (Sigma) added. Cell lysates were collected in RIPA buffer
containing 2 mg/ml Na3VO4 and the phosphorylated VEGFR2 level detected
either by ELISA (Cell Signaling, 7335 and 7340) or immunoblot using
antibodies to phospho-VEGFR2 (Y1175, rabbit; Cell Signaling, 2478;
1:500), VEGFR2 (mouse; Santa Cruz, sc-6251; 1:400), CRIM1 (mouse;
Sigma, WH0051232M1; 1:500) or α-tubulin (rabbit; Abcam, ab89984;
1:4000).
Quantitative RT-PCR
RNA was extracted using the RNeasy Micro Kit (Qiagen) and cDNA was
prepared using Superscript III reverse transcriptase (Invitrogen).
Quantitative PCR was performed with iQ SYBR Green Supermix (Bio-
Rad). Signals were detected using the Bio-Rad CFX1000 system and gene
expression levels were calculated using the standard curve method.
Fluorescence-activated cell sorting (FACS)
Freshly isolated mouse retinas were incubated in DMEM (Gibco) containing
1 mg/ml collagenase A (Roche) and 3 U/ml DNase I on a shaker at 37°C for
30 minutes with gentle pipetting every 10 minutes. Cells were passed
through cell strainers (BD Biosciences) and centrifuged at 500 g for
5 minutes. After washes in PBS containing 2 mM EDTA and reconstitution
in the same buffer, cells were labeled with PE-CD31 and APC-CD45 (Ptprc)
antibodies (BD Biosciences) at 4°C for 20 minutes. After washes, cells were
reconstituted in PBS containing 2 mM EDTA and passed through a cell
strainer again before FACS analysis. PE (CD31)-positive and APC (CD45)-
negative populations were sorted and collected as VECs.
Statistical analysis
Statistical analysis was performed using Student’s t-test.
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Fig. S1. Crimflox allele design and inducing VEC specific cre activity in PdgfbiCre mouse line. (A) Diagram of Crim1flox allele. 
(B) Genomic DNA PCR could distinguish mice with or without Crim1flox allele. In Crim1flox/flox;Pdgfb-iCreER and Crim1flox/+;Pdgfb-
iCreER mice injected with tamoxifen, a ‘deletion’ band showing recombination of the genomic DNA can also be detected using the 
tail tip genomic DNA. Lane1: Crim1flox/+. Lane2: Crim1flox/+;Pdgfb-iCreER. Lane3: Crim1flox/flox. Lane4: Crim1flox/flox;Pdgfb-iCreER. 
flox: Crim1flox; WT: wild type; iCre: Pdgfb-iCreER; Δflox: Crim1(EC)Δflox; bp: basepairs. (C) Tamoxifen injection plan of experiments 
in this paper. In most experiments, tamoxifen was injected daily to pups from date-of-birth (P1) to the day of analysis (P5, P6, P7). 
For experiment shown in Fig. S2, tamoxifen was injected starting from P7. (D) Specificity and efficiency of Pdgfb-iCreER line upon 
injection of tamoxifen. Cre activity was visualized by labeling of X-Gal in P5 retina preps from injected Pdgfb-iCreER;ROSA26R 
pups. (E) Detection of DNA recombination of targeted Crim1flox allele in tamoxifen injected, Pdgfb-iCreER positive pups
Fig. S2. Germ line Crim1 null mice exhibited multiple developmental defects. (A) Percentage of different genotypes in embryonic litters from intercrosses between Crim1Δflox/+ 
mice at different stages. Numbers in the bars represent total embryos collected. (B) Frequency of anomalous phenotypes observed in Crim1Δflox/ Δflox embryos collected at different 
stages. ND: not (old enough) to define a defect. (C-T) Representative images showing developmental defects in Crim1Δflox/ Δflox embryos. Stages and phenotypes are indicated. 
Hollow arrowheads: peridermal blebbing; filled arrowheads: hemorrhage or hematoma; yellow arrow: widespread edema. (I, J, M, N) Syndactyly in germ line Crim1 null mice 
often happen between digits 3 and 4. (O-P) Eye hypoplasia. (Q-R) Kidneys were mildly smaller in Crim1 null mice. Scale bars in (O-R): 500μm.
Fig. S3. Phenotype of deep layer retinal vasculature of Crim1 VEC conditional mutant mice. (A-D) Flat-Mounted P10 retinas 
labeled with isolectin IB4 showing deepest layer retinal vasculature (which is between out-plexus-layer and photo receptor layer) 
showed delayed vascularization of the retina. Tamoxifen was injected starting from P7 when vessel just started to sprout into the deep 
layer. (E-G) Quantitations of vertical sprouts, branchpoints in deep layer vasculature and vessel length in deep layer vasculature. Error 
bars represent s.e.m.
Fig. S4. Vegfr3 expression was not changed in Crim1 VEC conditional mutants. (A-D) Flat-mounted P6 mice retina preps labeled 
with Isolectin IB4 and Vegfr3 antibodies.
Fig. S5. Mural cell recruitment in Crim1 endothelial cell conditional mutant mice was not affected. (A-L) Flat-mounted P7 mice 
retina preps labeled with Isolectin IB4, desmin antibody (pericyte marker) and Smooth-muscle-actin antibody (smooth muscle cells 
marker).
Fig. S6. Vegfa VEC conditional mutant mice exhibited similar precocious regression phenotypes as Crim1 VEC conditional 
mutant mice. (A-H) Isolectin IB4, VE-Cadherin and Collagen IV labeling of angiogenic front vasculature in control (A-D) and 
VegfaloxP/loxP;Pdgfb-iCreER (E-H) littermates. Hollow arrowheads in (A,B,E,F) point to vessel ‘ghosts’, indicating vessel regression 
and filled arrowheads in (C,D,G,H) point to VE-Cadherin labeling discontinuous regions. (I-P) Isolectin IB4, VE-Cadherin and 
podocalyxin labeling of angiogenic front vasculature in control (I-L) and VegfaloxP/loxP;Pdgfb-iCreER (M-P) littermates. Filled 
arrowheads point to VE-Cadherin-labeling discontinuous regions where vessels also lack luminal marker labeling.
Fig. S7. Adhesion junctions and VEGFR2 level and distribution were not changed when CRIM1 and VEGFA were knocked down in cultured endothelial cells. (A-I) VE-
CADHERIN and β-CATENIN labeling with Hoechst staining in control HUVECs or HUVECs expressing shRNAs targeting CRIM1 and VEGFA. (J-R) VEGFR2 and GOLGA2 
labeling with Hoechst staining in control HUVECs or HUVECs with CRIM1 and VEGFA knock-down. GOLGA2 antibody was used to label Golgi apparatus.
Fig. S8. Crim1 was required for cultured endothelial cell survival. (A) Growth curve of control and CRIM1 knockdown HUVECs 
cultured in serum-free, VEGFA depleted medium. 20,000 cells were plated into each well of fibronectin coated 96-well plates at time 
zero. (B) VEGFR2 phosphorylation in response to different concentration of exogenous VEGFA stimulation. HUVECs infected with 
scramble shRNA or shRNA targeting CRIM1 were starved for 24 hours and stimulated with different concentration of recombinant 
VEGFA for 5 minutes. Cell lysates were applied to phospho-VEGFR2 and total VEGFR2 ELISAs and the ratio of the two readouts 
calculated. In one set of experiments, conditional medium with 20 ng/ml VEGFA added was incubated with 10 μg/ml Avastin 
for 2 hours before applied to the cells. In another set of experiments, cells was incubated with 0.5 μM SU5416 for 1 hour before 
stimulated with conditional medium containing 20 ng/ml VEGFA with same concentration of SU5416. Error bars represent s.e.m of 
three experiments. *: P<0.05; ***: P<0.005.
